Filtered By:
Therapy: Neoadjuvant Therapy
This page shows you your search results in order of date. This is page number 15.
Order by Relevance | Date
Total 9996 results found since Jan 2013.
Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections
CONCLUSION: Previous viral, bacterial and protozoal neurotropic infections appear not to be associated with the development of neurological irAEs in melanoma patients who underwent therapy with ICI across 3 countries. Further efforts are needed to unravel the factors underlying neurological irAEs in order to identify risk factors for these toxicities, especially with the increasing use of ICI in earlier stage disease.PMID:37606856 | DOI:10.1007/s00262-023-03498-0
Source: Herpes - August 22, 2023 Category: Infectious Diseases Authors: C Schmitt E P Hoefsmit T Fangmeier N Kramer C Kabakci J Vera Gonz ález J M Versluis A Compter T Harrer H Mijo čević S Schubert T Hundsberger A M Menzies R A Scolyer G V Long L E French C U Blank L M Heinzerling Source Type: research
18FFDG PET/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab
CONCLUSION: High tumor metabolism (SUVmax) and low tumor burden (TMTV) could predict pCR after NAC regardless of the addition of pembrolizumab. Further studies are warranted to validate such findings and determine how these biomarkers could be used to guide neoadjuvant therapy in TNBC patients.PMID:37606858 | DOI:10.1007/s00259-023-06394-y
Source: Molecular Medicine - August 22, 2023 Category: Molecular Biology Authors: Romain-David Seban Emilie Arnaud Delphine Loirat Luc Cabel Paul Cottu Lounes Djerroudi Segolene Hescot Pierre Loap Claire Bonneau Francois-Clement Bidard Virginie Huchet Nina Jehanno Arnaud Berenbaum Laurence Champion Irene Buvat Source Type: research
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma: a systematic review and meta-analysis
CONCLUSIONS: This meta-analysis provides preliminary evidence of the efficacy and safety of neoadjuvant immunotherapy for HCC, suggesting that it is a promising perioperative treatment option. Conclusive evidence supporting its use requires additional data from large-scale clinical trials.PMID:37606124 | DOI:10.26355/eurrev_202308_33287
Source: Pharmacological Reviews - August 22, 2023 Category: Drugs & Pharmacology Authors: Y-H Han J-Q Bo L-X Liu Source Type: research
Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial
CONCLUSION: Adding OFS for 2 years to adjuvant TAM with a longer follow-up resulted in consistent DFS benefits, suggesting that adding OFS to TAM should be considered for patients who remain in a premenopausal state or resume ovarian function after chemotherapy.PMID:37607321 | DOI:10.1200/JCO.23.00557
Source: Clinical Breast Cancer - August 22, 2023 Category: Cancer & Oncology Authors: Soo Yeon Baek Woo Chul Noh Sei-Hyun Ahn Hyun-Ah Kim Jai Min Ryu Seung Il Kim Eun-Gyeong Lee Seock-Ah Im Yongsik Jung Min Ho Park Kyong Hwa Park Su Hwan Kang Joon Jeong Eunhwa Park Sung Yong Kim Min Hyuk Lee Lee Su Kim Woosung Lim Seonok Kim Hee Jeong Kim Source Type: research
Discordant Breast and Axillary Pathologic Response to Neoadjuvant Chemotherapy
CONCLUSIONS: Discordance between breast and axillary pCR is not infrequent and may be related to a number of patient-related factors and tumor characteristics impacting nodal response to NAC. Further investigation into differing responses to NAC is warranted to better understand the mechanism of this phenomenon and to determine how these findings may influence treatment.PMID:37606840 | DOI:10.1245/s10434-023-14082-2
Source: Ann Oncol - August 22, 2023 Category: Cancer & Oncology Authors: Rene Flores Estefania Roldan Jaime A Pardo Leah Beight Jessalyn Ubellacker Betty Fan Roger B Davis Ted A James Source Type: research
Intraoperative Ultrasound-Guided Conserving Surgery for Breast Cancer: No More Time for Blind Surgery
CONCLUSIONS: IOUS allows real-time resection margin visualization and continuous control during BCS. It showed clear superiority over TS in both oncological and surgical outcomes for all breast cancer lesion types. These results disfavor the paradigm of blind breast surgery.PMID:37606837 | DOI:10.1245/s10434-023-13900-x
Source: Ann Oncol - August 22, 2023 Category: Cancer & Oncology Authors: Massimo Ferrucci Francesco Milardi Daniele Passeri Luaya Fabrizio Mpungu Andrea Francavilla Matteo Cagol Tania Saibene Silvia Michieletto Mariacristina Toffanin Paola Del Bianco Ugo Grossi Alberto Marchet Source Type: research
Timing is Everything: Neoadjuvant Versus Adjuvant Immunotherapy in Patients with Resectable Metastatic Melanoma
Ann Surg Oncol. 2023 Aug 19. doi: 10.1245/s10434-023-14133-8. Online ahead of print.NO ABSTRACTPMID:37597079 | DOI:10.1245/s10434-023-14133-8
Source: Ann Oncol - August 19, 2023 Category: Cancer & Oncology Authors: Ashley M Holder Jennifer A Wargo Merrick I Ross Source Type: research
Association of PIK3CA mutation with outcomes in HER2-positive breast cancer treated with anti-HER2 therapy: A meta-analysis and bioinformatic analysis of TCGA ‑BRCA data
CONCLUSIONS: PIK3CA mutation was significantly associated with a lower pCR rate in HER2-positive breast cancer treated with neoadjuvant anti-HER2 therapy. In the metastatic setting, PIK3CA mutation was predictive of worse ORR, PFS and TTP. These results suggest the potential for developing PI3K inhibitors as a therapeutic option for these patients.PMID:37597296 | DOI:10.1016/j.tranon.2023.101738
Source: Translational Oncology - August 19, 2023 Category: Cancer & Oncology Authors: Haizhu Chen Xingbin Hu Daquan Wang Ying Wang Yunfang Yu Herui Yao Source Type: research
ASO Author Reflections: Immune Microenvironment Indicators in Neoadjuvant Chemo-Immunotherapy
Ann Surg Oncol. 2023 Aug 19. doi: 10.1245/s10434-023-14151-6. Online ahead of print.NO ABSTRACTPMID:37598122 | DOI:10.1245/s10434-023-14151-6
Source: Ann Oncol - August 19, 2023 Category: Cancer & Oncology Authors: Tianxiang Chen Zhengqi Cao Yingjia Sun Jia Huang Shengping Shen Yueping Jin Long Jiang Fengcai Wen Xiaochen Zhao Ding Zhang Yanan Chen Mengli Huang Hao Chen Shun Lu Ziming Li Source Type: research
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030
CONCLUSION: NAT for TNBC reduced ctDNA TFx by 285-fold in responders and 24-fold in non-responders. In 58% (22/38) of patients, ctDNA TFx dropped below the detection level of a commercially available test, emphasizing the need for sensitive tests. Additional studies will determine if ctDNA-guided approaches can improve outcomes.PMID:37597579 | DOI:10.1016/j.annonc.2023.08.004
Source: Ann Oncol - August 19, 2023 Category: Cancer & Oncology Authors: H A Parsons T Blewett X Chu S Sridhar K Santos K Xiong V G Abramson A Patel J Cheng A Brufsky J Rhoades J Force R Liu T A Traina L A Carey M F Rimawi K D Miller V Stearns J Specht C Falkson H J Burstein A C Wolff E P Winer N Tayob I E Krop G M Makrigiorgo Source Type: research
Timing is Everything: Neoadjuvant Versus Adjuvant Immunotherapy in Patients with Resectable Metastatic Melanoma
Ann Surg Oncol. 2023 Aug 19. doi: 10.1245/s10434-023-14133-8. Online ahead of print.NO ABSTRACTPMID:37597079 | DOI:10.1245/s10434-023-14133-8
Source: Ann Oncol - August 19, 2023 Category: Cancer & Oncology Authors: Ashley M Holder Jennifer A Wargo Merrick I Ross Source Type: research
Monitoring of Triple Negative Breast Cancer After Neoadjuvant Chemotherapy
Clin Breast Cancer. 2023 Aug 5:S1526-8209(23)00208-2. doi: 10.1016/j.clbc.2023.08.001. Online ahead of print.ABSTRACTTriple negative breast cancer (TNBC) is an aggressive disease with a poor prognosis that disproportionately affects young women and African Americans, and represents a major unmet need in the field. TNBCs display a more aggressive growth pattern with an increased risk of advanced disease and high recurrence risk in patients with early stage TNBC. The addition of immunotherapy to chemotherapy for the treatment of patients with early stage TNBC in the (neo) adjuvant setting per the pivotal KEYNOTE 522 signific...
Source: Clinical Breast Cancer - August 18, 2023 Category: Cancer & Oncology Authors: Jeffrey Aldrich Madison Canning Manali Bhave Source Type: research
